Several phase I studies evaluated activity of anti PD-L1 agents in melanoma cohorts.MPDL3280A, an IgG1engineered anti PD-L1 antibody reported a 39% ORR with a 43%24-week progression free survival rate in 38 patients [15]. This evidence concerns the gene CD274 and melanoma.